LONG-TERM EFFECTS OF OLMESARTAN, AN ANG II RECEPTOR ANTAGONIST, ON BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
Abstract
The object of this study is to evaluate the long-term effects of olmesartan on hypertension and the renin-angiotensinaldosterone system in hypertensive patients. This study evaluated 26 hypertensive male and female outpatients, 38-69 years of age, with a systolic blood pressure ≥160 mm Hg and/or a diastolic blood pressure ≥95 mm Hg. Oral doses of 5 to 40 mg olmesartan were administered once daily. Blood pressure and renin-angiotensin-aldosterone parameters (plasma renin activity and plasma angiotensin I, II, and aldosterone concentrations) were evaluated at 12-16 weeks, 6 months, and 1 year after the start of olmesartan administration. Systolic and diastolic blood pressures were significantly decreased following the administration of olmesartan. The observed decreases in systolic and diastolic blood pressures after 1 year of treatment were 28,8±2,1 mm Hg and 15,8±1,3 mm Hg, respectively. No change was observed in the pulse rate. The plasma renin activity increased significantly from a baseline premedication mean of 1,26±0,31 ng/ml/h to a mean of 2,58±0,74 ng/ml/h and 2,87±0,72 ng/ml/h after 6 months and 1 year of treatment, respectively. Angiotensin II levels decreased significantly from a baseline of 20,4±3,2 pg/ml to a mean of 8,6±2,1 pg/ml and 6,8±1,8 pg/ml after 6 months and 1 year of treatment, respectively. The plasma aldosterone level also decreased significantly after 6 months of treatment. In hypertensive patients, the long-term administration of olmesartan, a novel AT, receptor antagonist, decreased both blood pressure and plasma angiotensin II levels.
About the Authors
Shuichi Ichikawa
Отдел медицины внутренних органов
Japan
Japan
Yoshiaki Takayama
Отдел медицины внутренних органов
Japan
Japan
References
1. I. Timmermans PB: Ang II receptor antagonists: an emerging new class of cardiovascular therapeutics // Hypertens Res 1999; 22: 147-153.
2. Mizuno M, Sada T, Ikeda M, et al: Pharmacology of CS866, a novel nonpeptide Ang II receptor antagonist // Eur J Pharmacol1995; 285: 181-188.
3. Yanagisawa H, Amemiya Y, Kanazaki T, et al: Nonpeptide Ang II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkcnyl, and hydroxyalkyl substituents at the 4-position and their related compounds // J Med Chem 1996; 39: 323-338.
4. Neutel JM: Clinical studies of CS-866, the newest angiotensin II receptor antagonist //Am J CardioI2000; 87: 37-43.
5. Puchler K, Nussherger J, Laeis P, Witte PU, Brunner HR: Blood pressure and endocrine effects of single doses of CS866, a novel Ang II antagonist, in salt-restricted hypertensive Patients// J Hypertens 1997; 15: 1809-1812.
6. Gavras I, Gavras H: Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26week, double-blind, multicentre study. Eprosartan Multinational Study Group// Curr Med Res Opin 1999; 15: 15-24.
7. Grossman E, Peleg E, Carroll J, Shamiss A, Rosenthal T: Hemodynamic and humoral effects of the angiotensin II antagonist Iosartan in essential hypertension// Am J Hypertens 1994; 7: 1041-1044.
8. Bauer IH, Reams GP, Wu Z, Lau-Sieckman A: Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension// J Hum Hypertens 1995; 9: 237-243.
9. Yamamoto T, Hiromoto J, Kikuchi Y, Oka M, Takatori 0: Correlations among blood levels of renin-angiotensin-aldosterone, bradykinin, and catecholamines in healthy subjects// Clin Chim Acta 1989; 181: 197-200.
10. Staessen JA, Gasowski J, Wang JG, et al: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials// Lancet 2000; 355: 865-872.
11. Millar JA, Lever AF, Burke V: Pulse pressure as a risk factor for cardiovascular events in the MRC mild hypertension trial// J Hypertens 1999; 17: 1065-1072.
12. Christen Y, Waeber B, Nussberger J, et al: Oral administration of DuP 753, a specific Ang II receptor antagonist, to normal male volunteers// Circulation 1991; 83: 1333-1342.
13. Goldberg MR, Tanaka W, Barehowsky A, et al: Effects of Iosartan on blood pressure, PRA, and Ang II in volunteers// Hypertension 1993; 21: 704-713.
14. Delacretaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR: Characterization of the Ang II receptor antagonist TCV-116 in healthy volunteers//Hypertension 1995;25: 14-21.
15. Fridman KU, Wysocki M, Friberg PR, Andersson OK: Candesartan cilexetil in hypertension: effects of six weeks’ treatment on haemodynamics, baroreceptor sensitivity and the renin-angiotensinaldosterone system// Blood Press 1999;8: 242-247.
16. Goldberg MR, Bradstreet TE, McWilliams EJ, et al: Biochemical effects of losartan, a nonpeptide Ang II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients// Hypertension 1995; 25: 37-46.
17. Nakamura A, Iwao H, Fukui K, et al: Regulation of liver angiotensinogen and kidney renin mRNA levels by Ang II// Am J Physiol 1990; 258: 1-6.
18. Gomez RA, Lynch KR, Chevalier RL, et al: Renin and angiotensinogen gene expression and intrarenal renin distribution during ACE inhibition//Am J Physioll988; 254: 900-906.
19. Shibasaki Y, Mori Y, Tsutsumi Y, et al: Differential kinetics of circulating Ang IV and II after treatment with Ang II type I receptor antagonist and their plasma levels in patients with chronic renal failure// Clin Nephrol 1999; 51: 83-91.
20. Siragy HM: The role of the AT2 receptor in hypertension// Am J Hypertens 2000; 13: 62-67.
Review
For citations:
Ichikawa Sh., Takayama Y. LONG-TERM EFFECTS OF OLMESARTAN, AN ANG II RECEPTOR ANTAGONIST, ON BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS. Russian Journal of Cardiology. 2011;(3):33-39. (In Russ.)
Views:
523
Email this article 